ALGS (Aligos Therapeutics, Inc.) Short-Term Debt to Capital

Aligos Therapeutics (ALGS) is a leading developer of small molecules and oligonucleotides for the treatment of NASH and chronic hepatitis B. As its primary projects are currently in clinical trial stages, cash flow remains negative, and financial stability relies on liquid reserves, which amount to 0.10. This chart reflects the asset's value and demonstrates the current state of debt, while the company develops a comprehensive therapy system for viral liver diseases.

This ratio measures the proportion of short-term liabilities within the equity structure, determining the company's ability to settle urgent debts without external support. By analyzing the change in debt under one year relative to equity on GURU.Markets, an investor assesses the risk of a cash gap for Aligos Therapeutics (ALGS), whose budget is critically dependent on R&D expenses and a lack of stable revenue.